United States - English - NLM (National Library of Medicine)

stratus pharamceuticals - magnesium hydroxide (unii: nbz3qy004s) (magnesium cation - unii:t6v3lhy838, hydroxide ion - unii:9159uv381p) - magnesium hydroxide 1200 mg in 15 ml

United States - English - NLM (National Library of Medicine)

belcher pharmaceuticals, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium cation 4.1 meq in 1 g - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. sodium polystyrene sulfonate for suspension is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, neonates with reduced gut motility (postoperatively or drug induced) and oral administration in neonates (see precautions).

United States - English - NLM (National Library of Medicine)

paddock laboratories, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 15 g in 60 ml - sodium polystyrene sulfonate suspension, usp is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, oral or rectal administration in neonates (particularly in premature infants), and in any post-operative patient until normal bowel function resumes (see precautions ).

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 15 g in 60 ml - sodium polystyrene sulfonate is indicated for the treatment of hyperkalemia. sodium polystyrene sulfonate is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, oral or rectal administration in neonates (see precautions ).

United States - English - NLM (National Library of Medicine)

atlantic biologicals corp - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 1 g in 1 g - sodium polystyrene sulfonate, usp is indicated for the treatment of hyperkalemia. sodium polystyrene sulfonate, usp is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, neonates with reduced gut motility (postoperatively or drug induced) and oral administration in neonates (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: ethylcellulose; titanium dioxide; mannitol; crospovidone; magnesium stearate; iron oxide yellow; diacetylated monoglycerides; heavy magnesium oxide; light magnesium oxide; purified talc; hyprolose; hypromellose phthalate - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: diacetylated monoglycerides; heavy magnesium oxide; light magnesium oxide; hyprolose; ethylcellulose; magnesium stearate; purified talc; crospovidone; mannitol; titanium dioxide; hypromellose phthalate; iron oxide yellow - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

United States - English - NLM (National Library of Medicine)

exela pharma sciences, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

United States - English - NLM (National Library of Medicine)

chain drug consortium, llc - magnesium hydroxide (unii: nbz3qy004s) (magnesium cation - unii:t6v3lhy838, hydroxide ion - unii:9159uv381p) - magnesium hydroxide 1200 mg in 15 ml - saline laxative - relieves occasional constipation (irregularity) - usually produces bowel movement in 1/2 to 6 hours

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838) - relieves: ■ acid indigestion  ■ upset stomach